Treatment failure is a key factor in the development of Helicobacter pylori resistance

IF 4.3 2区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Helicobacter Pub Date : 2024-05-23 DOI:10.1111/hel.13091

Jinliang Xie, Jianxiang Peng, Dingwei Liu, Rong Zeng, Jiayu Qiu, Liting Shen, Xiaomin Gong, Dongsheng Liu, Yong Xie

{"title":"Treatment failure is a key factor in the development of Helicobacter pylori resistance","authors":"Jinliang Xie, Jianxiang Peng, Dingwei Liu, Rong Zeng, Jiayu Qiu, Liting Shen, Xiaomin Gong, Dongsheng Liu, Yong Xie","doi":"10.1111/hel.13091","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p><i>Helicobacter pylori</i> eradication failure influences its antibiotic resistance.</p>\n </section>\n \n <section>\n \n <h3> Aims</h3>\n \n <p>This study aimed to evaluate the effect of previous treatment failures on it, including the changes in the antibiotic resistance rates, minimal inhibitory concentration (MIC) distributions, and resistance patterns.</p>\n </section>\n \n <section>\n \n <h3> Materials and Methods</h3>\n \n <p>This single-center retrospective study included 860 primary isolates and 247 secondary isolates. Antibiotic susceptibility testing was performed for amoxicillin, metronidazole, clarithromycin, levofloxacin, furazolidone, tetracycline, and rifampicin. The demographic data and detailed regimens were collected.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The primary resistance rates to amoxicillin, metronidazole, clarithromycin, levofloxacin, tetracycline, rifampin, and furazolidone were 5.93%, 83.84%, 28.82%, 26.28%, 0.35%, 1.16%, and 0%, while secondary were 25.10%, 92.31%, 79.76%, 63.16%, 1.06%, 3.19%, and 0%, respectively. The resistance rates to amoxicillin, metronidazole, clarithromycin, and levofloxacin increased significantly with the number of treatment failures accumulated, and showed a linear trend. The proportion of primary and secondary multidrug-resistant (MDR) isolates were 17.79% and 63.16%, respectively. The MIC values of amoxicillin, clarithromycin, and levofloxacin were elevated significantly with medication courses increased.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>The prevalence of amoxicillin, clarithromycin, levofloxacin, and metronidazole resistance would increase rapidly following first-line treatment failure, as well as the MIC values of them. Clinicians should pay great attention to the first-line treatment to cure <i>H. pylori</i> infection successfully.</p>\n </section>\n </div>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"29 3","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2024-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Helicobacter","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/hel.13091","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Helicobacter pylori eradication failure influences its antibiotic resistance.

Aims

This study aimed to evaluate the effect of previous treatment failures on it, including the changes in the antibiotic resistance rates, minimal inhibitory concentration (MIC) distributions, and resistance patterns.

Materials and Methods

This single-center retrospective study included 860 primary isolates and 247 secondary isolates. Antibiotic susceptibility testing was performed for amoxicillin, metronidazole, clarithromycin, levofloxacin, furazolidone, tetracycline, and rifampicin. The demographic data and detailed regimens were collected.

Results

The primary resistance rates to amoxicillin, metronidazole, clarithromycin, levofloxacin, tetracycline, rifampin, and furazolidone were 5.93%, 83.84%, 28.82%, 26.28%, 0.35%, 1.16%, and 0%, while secondary were 25.10%, 92.31%, 79.76%, 63.16%, 1.06%, 3.19%, and 0%, respectively. The resistance rates to amoxicillin, metronidazole, clarithromycin, and levofloxacin increased significantly with the number of treatment failures accumulated, and showed a linear trend. The proportion of primary and secondary multidrug-resistant (MDR) isolates were 17.79% and 63.16%, respectively. The MIC values of amoxicillin, clarithromycin, and levofloxacin were elevated significantly with medication courses increased.

Conclusion

The prevalence of amoxicillin, clarithromycin, levofloxacin, and metronidazole resistance would increase rapidly following first-line treatment failure, as well as the MIC values of them. Clinicians should pay great attention to the first-line treatment to cure H. pylori infection successfully.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

治疗失败是幽门螺旋杆菌产生抗药性的一个关键因素。

背景：幽门螺杆菌根除失败会影响其抗生素耐药性：目的：本研究旨在评估以往治疗失败对幽门螺杆菌的影响，包括抗生素耐药率、最小抑菌浓度（MIC）分布和耐药模式的变化：这项单中心回顾性研究包括 860 例初次分离株和 247 例二次分离株。对阿莫西林、甲硝唑、克拉霉素、左氧氟沙星、呋喃唑酮、四环素和利福平进行了抗生素药敏试验。收集了人口统计学数据和详细的治疗方案：阿莫西林、甲硝唑、克拉霉素、左氧氟沙星、四环素、利福平和呋喃唑酮的一级耐药率分别为5.93%、83.84%、28.82%、26.28%、0.35%、1.16%和0%，二级耐药率分别为25.10%、92.31%、79.76%、63.16%、1.06%、3.19%和0%。随着治疗失败次数的累积，阿莫西林、甲硝唑、克拉霉素和左氧氟沙星的耐药率显著增加，并呈线性趋势。原发性和继发性多重耐药（MDR）分离株的比例分别为 17.79% 和 63.16%。随着疗程的增加，阿莫西林、克拉霉素和左氧氟沙星的 MIC 值明显升高：结论：阿莫西林、克拉霉素、左氧氟沙星和甲硝唑的耐药性在一线治疗失败后会迅速增加，其 MIC 值也会增加。临床医生应高度重视一线治疗，以成功治愈幽门螺杆菌感染。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Helicobacter 医学-微生物学

CiteScore

8.40

自引率

9.10%

发文量

审稿时长

2 months

期刊介绍： Helicobacter is edited by Professor David Y Graham. The editorial and peer review process is an independent process. Whenever there is a conflict of interest, the editor and editorial board will declare their interests and affiliations. Helicobacter recognises the critical role that has been established for Helicobacter pylori in peptic ulcer, gastric adenocarcinoma, and primary gastric lymphoma. As new helicobacter species are now regularly being discovered, Helicobacter covers the entire range of helicobacter research, increasing communication among the fields of gastroenterology; microbiology; vaccine development; laboratory animal science.